Editor's Note: The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27 (local time). At the meeting, Professor Gustavo Werutsky of Moinhos de Vento Hospital in Porto Alegre, Brazil, presented patient-reported outcome (PRO) data from the phase III lidERA BC study (Abstract No. 538RO). The study evaluated the efficacy and safety of giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer. The PRO analysis showed that, alongside a significant improvement in invasive disease-free survival (iDFS), giredestrant effectively preserved patients' health-related quality of life (HRQoL) and daily functioning, while significantly reducing the burden of side effects and the risk of treatment discontinuation. Following his presentation, Oncology Frontier invited Professor Gustavo Werutsky for an interview to discuss the key findings and clinical implications of the lidERA BC PRO data, as well as their potential impact on the future landscape of adjuvant endocrine therapy.

Expert Interview

01

Oncology Frontier: At this year’s ESMO Congress, you presented the patient-reported outcome (PRO) data from the lidERA BC study. Could you first introduce the treatment-related findings and data presented at this meeting?

Professor Gustavo Werutsky: Hello, I am Gustavo Werutsky, a medical oncologist from Porto Alegre, Brazil. At ESMO 2026, I presented the PRO data from the phase III lidERA BC study, which evaluated the efficacy and safety of adjuvant giredestrant in patients with stage I–III ER+/HER2− early breast cancer.

As you may recall, we presented the primary endpoint results from lidERA BC at the San Antonio Breast Cancer Symposium (SABCS) in 2025. The primary results showed that giredestrant significantly improved invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy, with an approximately 3% improvement in 3-year iDFS (92.4% vs. 89.6%). The results also demonstrated that giredestrant had a safety profile characterized by low-grade, manageable toxicities. Interestingly, the rate of treatment discontinuation due to adverse events (AEs) was lower with giredestrant than with standard endocrine therapy (5.3% vs. 8.2%).

In the PRO analysis of lidERA BC that I presented, patients receiving giredestrant maintained their quality of life throughout the treatment period, as well as their role and physical functioning, with comparable results between the two treatment arms. As we know, this is essential for long-term treatment adherence.

We also found that joint pain was common, with approximately 60% of patients reporting it at study entry. However, more patients receiving giredestrant never reported joint pain during the study. Interestingly, when we compared giredestrant with standard endocrine therapy, we found that although the incidence of arthralgia as an adverse event was similar between the arms, the PRO data revealed a meaningful difference. During the first six months of treatment, the proportion of patients reporting that they had never experienced joint pain was approximately 6.0%–7.5% higher in the giredestrant arm than in the standard endocrine therapy arm. As you know, this is precisely the period when discontinuation of early endocrine therapy tends to occur more frequently.

Overall, the conclusion of the lidERA BC PRO analysis is that giredestrant not only improves efficacy compared with standard endocrine therapy in early breast cancer, but is also well tolerated and preserves patients’ quality of life.

02

Oncology Frontier: The PRO data from lidERA BC showed that both the giredestrant (GIRE) and standard-of-care endocrine therapy (SOC ET) arms maintained baseline physical and role functioning and HRQoL, with broadly comparable frequency and severity of key symptoms. However, at each assessment, the proportion of patients in the GIRE arm who reported being “not at all” bothered by side effects was 2%–8% higher. How do you interpret this phenomenon of “comparable symptom burden but less bother”? Does it suggest that giredestrant offers a distinct advantage in patients’ treatment tolerability experience?

Professor Gustavo Werutsky: We observed some very interesting findings regarding patients’ self-reported tolerability. First, more than 50% of patients receiving giredestrant reported that they were not bothered at all by its side effects, compared with patients receiving standard endocrine therapy.

Furthermore, approximately 80% of patients reported being either not bothered at all or bothered only a little by side effects. This proportion was higher in the giredestrant arm than in the standard endocrine therapy arm throughout treatment. These self-reported outcomes therefore provide further evidence of giredestrant’s favorable tolerability.

03

Oncology Frontier: Adjuvant endocrine therapy requires long-term adherence, and the degree to which side effects bother patients directly affects adherence and treatment outcomes. Considering the efficacy benefit demonstrated in lidERA BC and the current PRO findings, how do you think these results will influence the selection of adjuvant endocrine therapy and patient communication in clinical practice for ER+/HER2− early breast cancer? Are there plans for longer-term PRO follow-up or studies of patient preferences?

Professor Gustavo Werutsky: I believe the lidERA BC study has demonstrated clear efficacy for giredestrant monotherapy in patients with stage I–III, intermediate- to high-risk ER+/HER2− breast cancer, based on the three-year efficacy interim analysis of the primary endpoint that has already been reported.

When we analyzed the PRO data, we found fewer patient-reported symptoms with giredestrant than with standard endocrine therapy, particularly joint pain, as well as better self-reported tolerability. This helps explain why we observed a lower treatment discontinuation rate in the giredestrant arm than in the standard endocrine therapy arm in the clinical trial.

Therefore, with the emergence of a new endocrine agent that preserves quality of life, offers greater efficacy, and has a favorable safety profile, I believe this will certainly represent one of the major advances in early breast cancer. Just as aromatase inhibitors were approved 20 years ago, we will now have another treatment option that is effective, has a favorable safety profile, is associated with fewer discontinuations, and preserves quality of life with better tolerability.


Study Overview

Background

In the adjuvant treatment of early breast cancer, understanding the patient experience is essential, as long-term tolerability and health-related quality of life (HRQoL) directly affect treatment adherence and outcomes. The phase III lidERA BC study (NCT04961996; Bardia, SABCS 2025) demonstrated a significant efficacy benefit with giredestrant, an oral selective estrogen receptor degrader and complete estrogen receptor antagonist, compared with standard-of-care endocrine therapy (SOC ET). To complement the clinical efficacy data, this PRO analysis evaluated functioning, HRQoL, toxicity, and treatment burden from the patients’ perspective.

Methods

Patients with ER+/HER2− early breast cancer who had undergone surgery and (neo)adjuvant chemotherapy, if indicated, were randomized 1:1 to receive either giredestrant (GIRE) 30 mg once daily or SOC ET (tamoxifen or an aromatase inhibitor). Prespecified secondary and exploratory PRO endpoints were assessed at scheduled time points using the EORTC QLQ-C30, PRO-CTCAE, and FACT-G item GP5. Changes over time were analyzed descriptively.

Results

At the data cutoff (median follow-up, 32.3 months), questionnaire completion rates among the 4,170 patients at baseline were above 75% and remained above 75% during most treatment cycles.

Patients in both arms maintained baseline physical and role functioning and HRQoL during treatment, with no clinically meaningful deterioration (defined as a change of ≥10 points). The tolerability profiles were similar between the two arms, with most patients reporting key symptoms, including arthralgia, hot flashes, and fatigue, as occurring “occasionally,” being “mild,” or causing only “a little” bother, or less.

The proportions of patients whose key symptoms worsened to high severity levels (scores of 3 or 4) were comparable between the two arms, including arthralgia (43% with GIRE vs. 43% with SOC ET), hot flashes (32% vs. 31%), and fatigue (19% vs. 20%). Through Cycle 42, at each assessment time point, the proportion of patients reporting that they were “not at all” bothered by side effects was 2%–8% higher in the giredestrant arm than in the SOC ET arm.

Conclusions

The PRO data from lidERA BC indicate that giredestrant preserves daily functioning and HRQoL in patients with early breast cancer. Although the frequency and severity of key symptoms were comparable between the two arms, patients receiving giredestrant consistently reported less bother from side effects. Overall, the PRO findings suggest that the improved efficacy of giredestrant over SOC ET was not achieved at the expense of tolerability or HRQoL.

Professor Gustavo Werutsky